Form 4: J&J Executive Exercises Options, Sells Shares, Receives New Grants

A Johnson & Johnson executive exercised stock options and sold shares for liquidity and tax purposes, while also receiving new equity awards.

Summary

• John C. Reed, EVP, Innovative Medicine, R&D at Johnson & Johnson (JNJ), engaged in multiple equity transactions in February 2026.
• On February 15, 2026, Reed vested 1,349 Restricted Share Units (RSUs) from a 2024 award and 1,847 RSUs from a 2025 award, converting them into common stock.
• Concurrently, 913 common shares were sold at $243.45 to cover tax obligations arising from the RSU vestings.
• Reed also received new equity grants on February 15, 2026, including 49,382 Employee Stock Options with an exercise price of $243.45 and 3,546 Restricted Share Units (RSUs).
• On February 17, 2026, Reed exercised 21,721 Employee Stock Options at $157.92 and 29,927 Employee Stock Options at $156.15.
• Immediately following the option exercises, 51,648 common shares (21,721 + 29,927) were sold at $243 per share, likely as part of a 'cashless exercise' strategy.
• An additional 2,283 common shares were sold at $243 on February 17, 2026.
• Following all reported transactions, Reed's direct beneficial ownership of Johnson & Johnson common stock stands at 10,658 shares.
• Reed also beneficially owns 1,349 RSUs (from 2024 award), 3,692 RSUs (from 2025 award), 49,382 Employee Stock Options (from 2026 grant), and 3,546 RSUs (from 2026 grant), along with remaining unexercised options from prior grants.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's a net sale of common stock, it's primarily driven by option exercises and tax obligations, coupled with significant new equity grants, indicating continued executive alignment.

Positives

• The executive received significant new grants of 49,382 Employee Stock Options and 3,546 Restricted Share Units, indicating continued long-term incentive alignment with the company's performance.
• The exercise of stock options at prices significantly below the market sale price ($157.92 and $156.15 exercise prices vs. $243 sale price) demonstrates a substantial realized gain for the executive.

Negatives

• The executive sold a total of 53,931 common shares (including tax-related sales and open market sales) over the two transaction days, resulting in a net decrease in direct common stock ownership from 12,941 shares to 10,658 shares after all transactions on February 17, 2026.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports on insider equity transactions.

Industry Context

StockSavvy.ai notes that these transactions are routine for executives receiving equity-based compensation. The exercise of 'in-the-money' options and subsequent sale of shares for liquidity or tax purposes is a common practice across the pharmaceutical and broader corporate sectors. The simultaneous grant of new equity awards (options and RSUs) is typical for retaining and incentivizing senior leadership in large, established companies like Johnson & Johnson, aligning executive interests with long-term shareholder value.

Comparison to Industry Standards

• The pattern of exercising vested stock options and selling a portion of the acquired shares for liquidity or tax purposes is standard practice for executives across industries, including peers like Pfizer, Merck, and Novartis.
• The grant of new Restricted Share Units and Employee Stock Options is consistent with long-term incentive plans commonly observed in large-cap pharmaceutical companies, aiming to align executive compensation with multi-year performance goals.
• The reported transaction prices ($243.45 and $243 for sales, $157.92 and $156.15 for option exercises) reflect market conditions for JNJ stock at the time of the transactions, which is typical for such filings.

Stakeholder Impact

• Shareholders: The transactions represent routine executive compensation activities and do not indicate a change in company strategy or financial health. The executive's continued receipt of new equity awards suggests ongoing commitment.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The newly granted Employee Stock Options will vest in three equal annual installments beginning on the first anniversary of the grant date (February 15, 2026).
• The newly granted Restricted Share Units (from the 2026 award) will vest in three annual equal installments beginning on the first anniversary of the grant date (February 15, 2026).

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, including option exercises, RSU vestings, and sales for tax and liquidity purposes, alongside new equity grants. Such activities are common and do not typically signal a change in the company's fundamental outlook or warrant a shift in investment strategy. The executive remains significantly invested through new grants and remaining holdings, suggesting continued alignment with long-term company performance. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

Johnson & Johnson, JNJ, Insider Trading, Form 4, Stock Options, Restricted Share Units, Equity Compensation, Executive Compensation, Share Sale, Option Exercise